Barrons
10 Aug 2026, 11:23 UTC · 14w ago
This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.
Impact · against what's priced in
AbCellera's stock is reacting to positive clinical data for ABCL635, which shows a single dose reduces hot flash frequency. This introduces a new potential revenue driver and clinical success metric for the company's pipeline.
- ABCL+0.60
No priced-in read yet
- In context
The efficacy of ABCL635 in reducing hot flash frequency after a single dose provides positive clinical validation for a new treatment candidate.
Read from the article alone

Search tags




